[4-(3,5-Dichlorophenyl)phenyl]methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(3,5-Dichlorophenyl)phenyl]methanamine
• 化学式: C₁₃H₁₁Cl₂N
• mdl: MFCD09026482
• 分子量: 252.14
• InChiKey: RVCJLWYNIURGAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS PYRIMIDINE QUI INHIBENT LA KINASE DU LYMPHOME ANAPLASIQUE
  申请人：AMGEN INC

  公开号：WO2011143033A1

  公开（公告）日：2011-11-17

  Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  Formula I的化合物是一种有用的间变性淋巴瘤激酶抑制剂。Formula I的化合物具有以下结构：变量的定义在此提供。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。
• Iminopyridine Derivative and Use Thereof
  申请人：Yoshida Masato

  公开号：US20100016315A1

  公开（公告）日：2010-01-21

  Provided are an iminopyridine derivative having a selective α 1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like, and a screening method for a compound having an α 1D adrenergic receptor antagonistic action. An α 1D adrenergic receptor antagonist containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an α 1D adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with bladder outlet obstruction.

  提供了一种具有选择性α1D肾上腺素受体拮抗作用的咪唑吡啶衍生物，可用作预防或治疗下尿路疾病等药物，以及一种筛选具有α1D肾上腺素受体拮抗作用的化合物的方法。一种含有以下式子所表示的化合物或其盐的α1D肾上腺素受体拮抗剂：其中每个符号如规范中所定义，以及一种筛选用于预防或治疗下尿路疾病的具有α1D肾上腺素受体拮抗作用的药物的方法，该方法包括测量具有膀胱出口梗阻的大鼠膀胱平滑肌张力。
• Benzimidazole derivatives and their use as kdr kinase protein inhibitors
  申请人：Babin Didier

  公开号：US20080125418A1

  公开（公告）日：2008-05-29

  The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitotic agents.

  本发明揭示和声明了式（I）的苯并咪唑化合物：其中X是C-R2; Y是C-R2或C-R3; W和Z均为C-R3; R1是可选择取代的芳基，杂芳基或饱和的5-或6-成员单环杂环基或双环杂环基; A5是H或烷基; 或者是式（I）的立体异构体，外消旋体，对映异构体或二对映异构体或其药学上可接受的盐; 本发明还涉及使用式（I）的化合物治疗血管增殖障碍，无控制的血管生成，纤维化障碍，系膜细胞增殖障碍，代谢障碍，过敏，哮喘，血栓形成，神经系统疾病，视网膜病变，牛皮癣，类风湿性关节炎，糖尿病，肌肉退化，实体瘤和癌症的药物组合物，包括式（I）的化合物和一个或多个药学上可接受的辅料或稀释剂以及包括式（I）的化合物和一个或多个抗有丝分裂剂的药物组合物。
• PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE
  申请人：Bryan Marian C.

  公开号：US20130158019A1

  公开（公告）日：2013-06-20

  Compounds of Formula I are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物是阻断无形淋巴瘤激酶的有用抑制剂。公式I的化合物具有以下结构：其中变量的定义在此提供。